Pivotal COVID Drug Trial Fully Enrolls, IDMC Gives Positive Safety Nod; Invivyd Reports Doubled Revenue
IVVD has more than doubled off its 52-week low of $0.46.
Summary
Invivyd reported robust Q4 and full-year 2025 financial results, with PEMGARDA revenue more than doubling year-over-year and operating expenses nearly halved. More significantly, the company announced its pivotal DECLARATION clinical trial for VYD2311, a COVID prevention candidate, has achieved full enrollment. An Independent Data Monitoring Committee (IDMC) completed an early safety review, making positive recommendations such as allowing pregnant and breastfeeding women to participate and reducing required safety visits, strongly indicating a favorable safety profile. These developments are highly material for a biotech company, de-risking the lead candidate and accelerating its path to potential commercialization. Additionally, Invivyd plans a Phase 2 trial for VYD2311 in Long COVID/vaccine injury and received aligned FDA advice for its LIBERTY Phase 3 trial, expanding its pipeline. Traders will now focus on the upcoming trial up-sizing decision in April and future efficacy data from DECLARATION.
At the time of this announcement, IVVD was trading at $1.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $473.9M. The 52-week trading range was $0.46 to $3.07. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.